Ben Zeskind, PhD

Ben Zeskind, Ph.D. has served as Immuneering's Co-Founder, President and Chief Executive Officer and a member of its board of directors since February 2008. Dr. Zeskind received his S.B. in electrical engineering and computer science and his Ph.D. in bioengineering from Massachusetts Institute of Technology (MIT), and his M.B.A. from Harvard Business School, where he was recognized as a Baker Scholar, the highest award for distinction. Immuneering was established based on a shared singular vision; to help people with cancer live longer without compromising quality of life during treatment. The company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. The company expects to dose the first patient in mid-2026 in MAPKeeper 301, a globally randomized pivotal Phase 3 trial evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. Immuneering's development pipeline also includes additional combination opportunities and early-stage programs.